CD19 and B-cell chronic lymphocytic leukemia: In 11 patients with relapsed or refractory CD19-positive non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL), NK cells modified to express an anti-CD19 CAR resulted in eight responses [8].